---
title: "mRNA Therapies"
slug: "mrna-therapies"
discipline: "Medicine / Biotechnology"
description: "mRNA-based therapeutics and vaccines. From COVID-19 vaccines to cancer immunotherapy, personalized medicine, and next-generation mRNA delivery platforms."
icon: "💉"
url: "https://science-database.com/technology/mrna-therapies"
api: "https://science-database.com/api/v1/technology/mrna-therapies"
llms_txt: "https://science-database.com/technology/mrna-therapies/llms.txt"
articles_indexed: 25
last_updated: "2026-04-11T06:14:06.182Z"
search_terms:
  - "mRNA vaccine therapy"
  - "mRNA lipid nanoparticle delivery"
  - "mRNA cancer immunotherapy"
source: "science-database.com"
license: "metadata CC0, abstracts belong to respective publishers"
---

# mRNA Therapies

mRNA-based therapeutics and vaccines. From COVID-19 vaccines to cancer immunotherapy, personalized medicine, and next-generation mRNA delivery platforms.

**Discipline:** Medicine / Biotechnology  
**Indexed Papers:** 25  
**Last Updated:** 2026-04-11

## Top Publications

Ranked by citation impact across Semantic Scholar, OpenAlex & arXiv.

### Clinical advances and ongoing trials of mRNA vaccines for cancer treatment

- **Authors:** Cathrine Lund Lorentzen, John B.A.G. Haanen, Özcan Met, Inge Marie Svane
- **Journal:** The Lancet Oncology
- **Published:** 2022-09-26
- **DOI:** [10.1016/s1470-2045(22)00372-2](https://doi.org/10.1016/s1470-2045(22)00372-2)
- **Citations:** 474
- **Source:** OpenAlex
- **Access:** Open Access
- **PDF:** [Download](http://www.thelancet.com/article/S1470204522003722/pdf)
- **llms.txt:** [View](https://science-database.com/technology/mrna-therapies/paper/oa-W4297102201/llms.txt)

### Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort

- **Authors:** Ulf Geisen, Dennis K Berner, Florian Tran, Melike Sümbül, Lena Vullriede, Maria Ciripoi, Hayley M Reid, Annika Schaffarzyk, Ann Carolin Longardt, Jeanette Franzenburg, Paula Hoff, Jan Henrik Schirmer, Rainald Zeuner, Anette Friedrichs, Andrea Steinbach, Christine Knies, Robert Markewitz, Peter J. Morrison, Sascha Gerdes, Stefan Schreiber, Bimba F. Hoyer
- **Journal:** Annals of the Rheumatic Diseases
- **Published:** 2021-03-24
- **DOI:** [10.1136/annrheumdis-2021-220272](https://doi.org/10.1136/annrheumdis-2021-220272)
- **Citations:** 376
- **Source:** OpenAlex
- **Access:** Open Access
- **PDF:** [Download](https://ard.bmj.com/content/annrheumdis/80/10/1306.full.pdf)
- **llms.txt:** [View](https://science-database.com/technology/mrna-therapies/paper/oa-W3139490202/llms.txt)

> We show that SARS-CoV-2 mRNA vaccines lead to development of antibodies in immunosuppressed patients without considerable side effects or induction of disease flares. Despite the small size of this cohort, we were able to demonstrate the efficiency and safety of mRNA vaccines in our cohort.

### Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies

- **Authors:** Anat Achiron, Mathilda Mandel, Sapir Dreyer-Alster, Gil Harari, David Magalashvili, Polina Sonis, Mark Dolev, Shay Menascu, Shlomo Flechter, Rina Falb, Michael Gurevich
- **Journal:** Therapeutic Advances in Neurological Disorders
- **Published:** 2021-01-01
- **DOI:** [10.1177/17562864211012835](https://doi.org/10.1177/17562864211012835)
- **Citations:** 361
- **Source:** OpenAlex
- **Access:** Open Access
- **PDF:** [Download](https://doi.org/10.1177/17562864211012835)
- **llms.txt:** [View](https://science-database.com/technology/mrna-therapies/paper/oa-W3158831599/llms.txt)

> Cladribine treatment does not impair humoral response to COVID-19 vaccination. We recommend postponing ocrelizumab treatment in MS patients willing to be vaccinated as a protective humoral response can be expected only in some. We do not recommend vaccinating MS patients treated with fingolimod as a protective humoral response is not expected.

### Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study

- **Authors:** Matthias B. Moor, Franziska Suter‐Riniker, Michael P. Horn, Daniel Aeberli, Jennifer Amsler, Burkhard Möller, Linet Njue, Cesare Medri, Anne Angelillo‐Scherrer, Luca Borradori, Susanne Radonjic‐Hoesli, S. Morteza Seyed Jafari, Andrew Chan, Robert Hoepner, Ulrike Bacher, Laila‐Yasmin Mani, Joseena Iype, Cédric Hirzel, Britta Maurer, Daniel Sidler
- **Journal:** The Lancet Rheumatology
- **Published:** 2021-09-07
- **DOI:** [10.1016/s2665-9913(21)00251-4](https://doi.org/10.1016/s2665-9913(21)00251-4)
- **Citations:** 211
- **Source:** OpenAlex
- **Access:** Open Access
- **PDF:** [Download](http://www.thelancet.com/article/S2665991321002514/pdf)
- **llms.txt:** [View](https://science-database.com/technology/mrna-therapies/paper/oa-W3197504359/llms.txt)

### Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy—A Single-Center Prospective Cohort Study

- **Authors:** Ron Ram, David Hagin, Nino Kikozashvilli, Tal Freund, Odelia Amit, Yael Bar‐On, Ofrat Beyar‐Katz, Gabi Shefer, M. Morales, Chen Karni, Ronit Gold, Sigi Kay, Chen Glait‐Santar, Rinat Eshel, Chava Perry, Irit Avivi, Arie Apel, Noam Benyamini, David Shasha, Ronen Ben‐Ami
- **Journal:** Transplantation and Cellular Therapy
- **Published:** 2021-06-30
- **DOI:** [10.1016/j.jtct.2021.06.024](https://doi.org/10.1016/j.jtct.2021.06.024)
- **Citations:** 162
- **Source:** OpenAlex
- **Access:** Open Access
- **PDF:** [Download](https://doi.org/10.1016/j.jtct.2021.06.024)
- **llms.txt:** [View](https://science-database.com/technology/mrna-therapies/paper/oa-W3175432865/llms.txt)

> Data are scarce regarding both the safety and immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in patients undergoing immune cell therapy; thus, we prospectively evaluated these two domains in patients receiving this vaccine after allogeneic hematopoietic cell transplantation (HCT; n = 66) or after CD19-based chimeric antigen receptor T cell (CART) therapy (n = 14). Overall, the vaccine was we...

### mRNA vaccine in cancer therapy: Current advance and future outlook

- **Authors:** Youhuai Li, Mina Wang, Xueqiang Peng, Yingying Yang, Qishuang Chen, Jiaxing Liu, Qi She, Jichao Tan, Chuyuan Lou, Zehuan Liao, Xuexin Li
- **Journal:** Clinical and Translational Medicine
- **Published:** 2023
- **DOI:** [10.1002/ctm2.1384](https://doi.org/10.1002/ctm2.1384)
- **Citations:** 106
- **Source:** Semantic Scholar
- **Access:** Open Access
- **PDF:** [Download](https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ctm2.1384)
- **llms.txt:** [View](https://science-database.com/technology/mrna-therapies/paper/s2-b0e74ce3268df667580d25e4f6fe24a10f1bd662/llms.txt)

> This review elaborated on the development of cancer vaccines and mRNA cancer vaccines, as well as the potential biological mechanisms of mRNA cancer vaccine and the latest progress in various tumour treatments, and discussed the challenges and future directions for the field.

### Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect

- **Authors:** Mariola Fotin‐Mleczek, Kai Zanzinger, Regina Heidenreich, Christina Lorenz, Andreas Theß, Katharina M. Duchardt, Karl‐Josef Kallen
- **Journal:** The Journal of Gene Medicine
- **Published:** 2012-01-20
- **DOI:** [10.1002/jgm.2605](https://doi.org/10.1002/jgm.2605)
- **Citations:** 105
- **Source:** OpenAlex
- **Access:** Open Access
- **PDF:** [Download](https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/jgm.2605)
- **llms.txt:** [View](https://science-database.com/technology/mrna-therapies/paper/oa-W1594820532/llms.txt)

> Direct vaccination with mRNA encoding tumor antigens is a novel and promising approach in cancer immunotherapy. CureVac's mRNA vaccines contain free and protamine-complexed mRNA. Such two-component mRNA vaccines support both antigen expression and immune stimulation. These self-adjuvanting RNA vaccines, administered intradermally without any additional adjuvant, induce a comprehensive balanced imm...

### Personalized pancreatic cancer therapy: from the perspective of mRNA vaccine

- **Authors:** Xing Huang, Gang Zhang, Tianyu Tang, Xiang Gao, T. Liang
- **Journal:** Military Medical Research
- **Published:** 2022
- **DOI:** [10.1186/s40779-022-00416-w](https://doi.org/10.1186/s40779-022-00416-w)
- **Citations:** 82
- **Source:** Semantic Scholar
- **Access:** Open Access
- **PDF:** [Download](https://mmrjournal.biomedcentral.com/counter/pdf/10.1186/s40779-022-00416-w)
- **llms.txt:** [View](https://science-database.com/technology/mrna-therapies/paper/s2-c85fe2a4ce6d3f317d7d85fa74a82ec0ef751a10/llms.txt)

> This review summarizes the current progress on pancreatic cancer vaccines, highlights the superiority of mRNA vaccines over other conventional vaccines, and proposes the viable tactic for designing and applying personalized mRNA vaccines for the precise treatment of Pancreatic cancer.

### An Integrated Polymeric mRNA Vaccine without Inflammation Side Effects for Cellular Immunity Mediated Cancer Therapy

- **Authors:** Pei Huang, Lingsheng Jiang, Hui-Ting Pan, Lingwen Ding, Bo Zhou, Mengyao Zhao, Jianhua Zou, Benhao Li, Meiwei Qi, Hongzhang Deng, Yongfeng Zhou, Xiaoyuan Chen
- **Journal:** Advanced Materials
- **Published:** 2022
- **DOI:** [10.1002/adma.202207471](https://doi.org/10.1002/adma.202207471)
- **Citations:** 63
- **Source:** Semantic Scholar
- **llms.txt:** [View](https://science-database.com/technology/mrna-therapies/paper/s2-82ac5673e1057b8473012e8dde0f70252aef6dc2/llms.txt)

> Unlike LNPs exhibiting high levels of inflammation, the PHTA‐based PNPs show negligible inflammatory side effects in vivo and provides a potential approach for establishing mRNA cancer vaccines with good inflammatory safety profiles.

### Could artificial intelligence revolutionize the development of nanovectors for gene therapy and mRNA vaccines?

- **Authors:** Akbar Hasanzadeh, Michael R. Hamblin, Jafar Kiani, Hamid Noori, Joseph Hardie, Mahdi Karimi, Hadi Shafiee
- **Journal:** Nano Today
- **Published:** 2022-11-07
- **DOI:** [10.1016/j.nantod.2022.101665](https://doi.org/10.1016/j.nantod.2022.101665)
- **Citations:** 60
- **Source:** OpenAlex
- **Access:** Open Access
- **PDF:** [Download](https://pmc.ncbi.nlm.nih.gov/articles/PMC10081506/pdf/nihms-1848688.pdf)
- **llms.txt:** [View](https://science-database.com/technology/mrna-therapies/paper/oa-W4308374489/llms.txt)

### Combination therapy with oncolytic virus and T cells or mRNA vaccine amplifies antitumor effects

- **Authors:** Rao Fu, Ruoyao Qi, Hualong Xiong, Xing Lei, Yao Jiang, Jinhang He, Feng Chen, Liang Zhang, Dekui Qiu, Yiyi Chen, Meifeng Nie, Xueran Guo, Yuhe Zhu, Jinlei Zhang, Mingxi Yue, Jiali Cao, Guosong Wang, Y. Que, Mujin Fang, Yingbin Wang, Yixin Chen, Tong Cheng, Sheng X. Ge, Jun Zhang, Quan Yuan, Tianying Zhang, Ningshao Xia
- **Journal:** Signal Transduction and Targeted Therapy
- **Published:** 2024
- **DOI:** [10.1038/s41392-024-01824-1](https://doi.org/10.1038/s41392-024-01824-1)
- **Citations:** 54
- **Source:** Semantic Scholar
- **Access:** Open Access
- **PDF:** [Download](https://www.nature.com/articles/s41392-024-01824-1.pdf)
- **llms.txt:** [View](https://science-database.com/technology/mrna-therapies/paper/s2-20b58b2d6f1ae4b5925e6234a98c43641e813de7/llms.txt)

> A rational combination therapy of OVs with adoptive T-cell transfer or mRNA vaccines encoding tumor-associated antigens is proposed, in terms of synergistic efficacy and mechanism.

### Nonviral Delivery Systems of mRNA Vaccines for Cancer Gene Therapy

- **Authors:** Yusi Wang, Rui Zhang, Lin Tang, Yang Li
- **Journal:** Pharmaceutics
- **Published:** 2022-02-25
- **DOI:** [10.3390/pharmaceutics14030512](https://doi.org/10.3390/pharmaceutics14030512)
- **Citations:** 50
- **Source:** OpenAlex
- **Access:** Open Access
- **PDF:** [Download](https://www.mdpi.com/1999-4923/14/3/512/pdf?version=1645801559)
- **llms.txt:** [View](https://science-database.com/technology/mrna-therapies/paper/oa-W4214722892/llms.txt)

> In recent years, the use of messenger RNA (mRNA) in the fields of gene therapy, immunotherapy, and stem cell biomedicine has received extensive attention. With the development of scientific technology, mRNA applications for tumor treatment have matured. Since the SARS-CoV-2 infection outbreak in 2019, the development of engineered mRNA and mRNA vaccines has accelerated rapidly. mRNA is easy to pro...

### mRNA: Vaccine or Gene Therapy? The Safety Regulatory Issues

- **Authors:** H. Banoun
- **Journal:** International Journal of Molecular Sciences
- **Published:** 2023
- **DOI:** [10.3390/ijms241310514](https://doi.org/10.3390/ijms241310514)
- **Citations:** 30
- **Source:** Semantic Scholar
- **Access:** Open Access
- **PDF:** [Download](https://www.mdpi.com/1422-0067/24/13/10514/pdf?version=1687855325)
- **llms.txt:** [View](https://science-database.com/technology/mrna-therapies/paper/s2-160bc6bad150573513b15b213f96b7ea6d56dc7f/llms.txt)

> The mode of action of COVID-19 mRNA vaccines should classify them as gene therapy products (GTPs), but they have been excluded by regulatory agencies, and in-depth vaccinovigilance should be carried out.

### Combination therapy of KRAS G12V mRNA vaccine and pembrolizumab: clinical benefit in patients with advanced solid tumors

- **Authors:** Xinjing Wang, Wei Wang, S. Zou, Zhiwei Xu, Dan Cao, Shuai Zhang, M. Wei, Qian Zhan, C. Wen, Fanlu Li, Hao Chen, Da Fu, Lingxi Jiang, Ming Zhao, Baiyong Shen
- **Journal:** Cell Research
- **Published:** 2024
- **DOI:** [10.1038/s41422-024-00990-9](https://doi.org/10.1038/s41422-024-00990-9)
- **Citations:** 28
- **Source:** Semantic Scholar
- **Access:** Open Access
- **PDF:** [Download](https://www.nature.com/articles/s41422-024-00990-9.pdf)
- **llms.txt:** [View](https://science-database.com/technology/mrna-therapies/paper/s2-916c614c59881d04948767ae77937d131023af40/llms.txt)

> This first-in-human study demonstrated the safety and preliminary effectiveness of mRNA vaccines targeting multiple neoantigens in 13 patients with advanced melanoma and suggested that utilizing personalized vaccines to cover multiple neoantigens in the postsurgical setting with a low tumor load is a practical strategy for mRNA therapeutics.

### Phase 1/2 study of mRNA vaccine therapy + durvalumab (durva) ± tremelimumab (treme) in patients with metastatic non-small cell lung cancer (NSCLC).

- **Authors:** Leena Gandhi, Kristen Aufiero Ramirez, Paul Schwarzenberger, Toni Ricciardi, Mary Macri, Aileen Ryan, Ralph Venhaus
- **Journal:** Journal of Clinical Oncology
- **Published:** 2018-05-20
- **DOI:** [10.1200/jco.2018.36.15_suppl.tps9107](https://doi.org/10.1200/jco.2018.36.15_suppl.tps9107)
- **Citations:** 16
- **Source:** OpenAlex
- **llms.txt:** [View](https://science-database.com/technology/mrna-therapies/paper/oa-W2891449256/llms.txt)

> TPS9107 Background: Vaccine therapies stimulate the immune system to attack cancer cells (active immunotherapy), whereas checkpoint inhibitors block immune inhibition (passive immunotherapy). Several PD-1 and PD-L1 blocking antibodies are approved for NSCLC. This study combines active and passive immunotherapies to determine if the addition of a mRNA vaccine can enhance the activity of checkpoint ...

### Phase 1/2 study of mRNA vaccine therapy + durvalumab (durva) ± tremelimumab (treme) in patients with metastatic non-small cell lung cancer (NSCLC).

- **Authors:** L. Gandhi, K. Ramirez, P. Schwarzenberger, T. Ricciardi, M. Macri, A. Ryan, R. Venhaus
- **Journal:** Journal of Clinical Oncology
- **Published:** 2018
- **DOI:** [10.1200/JCO.2018.36.15_SUPPL.TPS9107](https://doi.org/10.1200/JCO.2018.36.15_SUPPL.TPS9107)
- **Citations:** 13
- **Source:** Semantic Scholar
- **llms.txt:** [View](https://science-database.com/technology/mrna-therapies/paper/s2-70039aca56db47e9d00c0e3adde4e01fa05f8e58/llms.txt)

> The immune system is stimulated to attack cancer cells with checkpoint inhibitors, whereas checkpoint inhibitors block immune inhibition, and vaccine therapies stimulate the immune system to attackcancer cells with a different effect on survival.

### Abstract B209: Phase 1/2 study of mRNA vaccine therapy + durvalumab (durva) ± tremelimumab (treme) in patients with metastatic non-small cell lung cancer (NSCLC)

- **Authors:** Joshua K. Sabari, Kristen Aufiero Ramirez, Paul Schwarzenberger, Toni Ricciardi, Mary Macri, Aileen Ryan, Ralph Venhaus
- **Journal:** Cancer Immunology Research
- **Published:** 2019-02-01
- **DOI:** [10.1158/2326-6074.cricimteatiaacr18-b209](https://doi.org/10.1158/2326-6074.cricimteatiaacr18-b209)
- **Citations:** 13
- **Source:** OpenAlex
- **llms.txt:** [View](https://science-database.com/technology/mrna-therapies/paper/oa-W2912439624/llms.txt)

> Abstract Vaccine therapies stimulate the immune system to attack cancer cells (active immunotherapy), whereas checkpoint inhibitors block immune inhibition (passive immunotherapy). BI 1361849 (formerly CV9202) is a cancer vaccine comprising 6 mRNA constituents, each of which encodes for one of the non-small cell lung cancer (NSCLC) associated antigens: MUC1, survivin, NY-ESO-1, 5T4, MAGE-C2, and M...

### Nanostructured lipid carriers based mRNA vaccine leads to a T cell–inflamed tumour microenvironment favourable for improving PD-1/PD-L1 blocking therapy and long-term immunity in a cold tumour model

- **Authors:** Carole Fournier, Marion Mercey-Ressejac, V. Derangère, Amal Al Kadi, David Rageot, Christine Charrat, Alexis Leroy, Julien Vollaire, Véronique Josserand, Marie Escudé, Séverine Escaich, François Ghiringhelli, T. Decaens, Fabrice P. Navarro, Evelyne Jouvin-Marche, Patrice N. Marche
- **Journal:** eBioMedicine
- **Published:** 2025
- **DOI:** [10.1016/j.ebiom.2024.105543](https://doi.org/10.1016/j.ebiom.2024.105543)
- **Citations:** 12
- **Source:** Semantic Scholar
- **llms.txt:** [View](https://science-database.com/technology/mrna-therapies/paper/s2-fa97a63503a8e499b3b8087e8bc7922d7f810bae/llms.txt)

> Nostructured lipid carriers, the so-called Lipidots®, are effective platform for the development of vaccines against cancer based on mRNA delivery and combination with immune checkpoint blockers could counter tumour resistance and promote long-term antitumour immunity.

### Photosynthetic Bacteria‐Hitchhiking 2D iMXene‐mRNA Vaccine to Enable Photo‐Immunogene Cancer Therapy

- **Authors:** Shen Zhang, Jifeng Yu, Yunyun Liu, Bing Xiong, Yan Fang, Yu-Li Zhu, Shaoyue Li, Liping Sun, Boyang Zhou, Yikang Sun, Lifan Wang, Wenwen Yue, Haohao Yin, Huixiong Xu
- **Journal:** Advanced Science
- **Published:** 2024
- **DOI:** [10.1002/advs.202307225](https://doi.org/10.1002/advs.202307225)
- **Citations:** 11
- **Source:** Semantic Scholar
- **Access:** Open Access
- **PDF:** [Download](https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/advs.202307225)
- **llms.txt:** [View](https://science-database.com/technology/mrna-therapies/paper/s2-d0a113c0607c031a58415f3671cac32242190661/llms.txt)

> This study provides an innovative and effective paradigm for tumor immunotherapy, i.e., photo‐immunogene cancer therapy, and establishes an efficient delivery platform for mRNA vaccines, thereby opening a new path for the wide application of mRNA vaccines.

### Advances in mRNA vaccine therapy for breast cancer research

- **Authors:** Jia-Ying Li, Rui-yuan Jiang, Jia Wang, Xiao-jia Wang
- **Journal:** Discover Oncology
- **Published:** 2025
- **DOI:** [10.1007/s12672-025-02542-y](https://doi.org/10.1007/s12672-025-02542-y)
- **Citations:** 8
- **Source:** Semantic Scholar
- **llms.txt:** [View](https://science-database.com/technology/mrna-therapies/paper/s2-e9d79dea293a58c6ed45124005d197cce21e93fd/llms.txt)

> This review systematically examines the principles, mechanisms, advantages, key targets, and recent progress in mRNA vaccine therapy for breast cancer, and discusses current challenges and suggests potential directions for future research.

### Innovative mRNA Vaccine Approaches in Targeting Atherosclerosis: A New Era in Cardiovascular Therapy

- **Authors:** Rahul Kumar, Gowri Krishnaperumal, Chitra Vellapandian
- **Journal:** Cureus
- **Published:** 2024
- **DOI:** [10.7759/cureus.74141](https://doi.org/10.7759/cureus.74141)
- **Citations:** 8
- **Source:** Semantic Scholar
- **llms.txt:** [View](https://science-database.com/technology/mrna-therapies/paper/s2-0ec0aa5a454f0cec01f1eb7499c0ab85f542f3a4/llms.txt)

> This review explores emerging mRNA vaccine strategies targeting the complex mechanisms of atherosclerosis that could produce therapeutic proteins to modulate inflammation by encoding sequences that inhibit pro-inflammatory cytokines such as interleukin-1β, interleukin-6, and tumor necrosis factor-alpha, stabilizing plaques.

### Abstract B209: Phase 1/2 study of mRNA vaccine therapy + durvalumab (durva) ± tremelimumab (treme) in patients with metastatic non-small cell lung cancer (NSCLC)

- **Authors:** Joshua Sabari, K. Ramirez, P. Schwarzenberger, T. Ricciardi, M. Macri, A. Ryan, R. Venhaus
- **Journal:** Trials in Progress
- **Published:** 2019
- **DOI:** [10.1158/2326-6074.CRICIMTEATIAACR18-B209](https://doi.org/10.1158/2326-6074.CRICIMTEATIAACR18-B209)
- **Citations:** 7
- **Source:** Semantic Scholar
- **llms.txt:** [View](https://science-database.com/technology/mrna-therapies/paper/s2-9037d851688de31d3bbb56716a80296ade6c21c6/llms.txt)

> This ongoing phase 1/2, open-label study evaluates the safety and efficacy of BI 1361849 when administered with durva (Arm A) or durva + treme (Arm B) in patients with NSCLC to determine if the addition of a mRNA vaccine can enhance the activity of checkpoint blockade.

### Biomimetic Nanoparticle Based Targeted mRNA Vaccine Delivery as a Novel Therapy for Glioblastoma Multiforme

- **Authors:** T. Ahmed, Kazi Tasnuva Alam
- **Journal:** AAPS PharmSciTech
- **Published:** 2025
- **DOI:** [10.1208/s12249-025-03065-z](https://doi.org/10.1208/s12249-025-03065-z)
- **Citations:** 7
- **Source:** Semantic Scholar
- **llms.txt:** [View](https://science-database.com/technology/mrna-therapies/paper/s2-b982cc7292677ef6f931cccf4033d2c6f5d48516/llms.txt)

> The potential of using biomimetic nanoparticles to improve the specificity and effectiveness of mRNA vaccine against GBM is explored, which could impact the management of this deadly disease and improve patient outcomes by integrating cutting-edge nanotechnology with immunotherapy.

### Thiourea-modified poly(l-lysine) carriers with multiple hydrogen bonding interactions for safe and robust mRNA vaccine therapy.

- **Authors:** Jiangai Long, Sheng Ma, Renming Wan, Aolin Sun, Zhenyi Zhu, Ruoyi Wang, Zhaopei Guo, Wantong Song
- **Journal:** Journal of controlled release : official journal of the Controlled Release Society
- **Published:** 2025
- **DOI:** [10.1016/j.jconrel.2025.114371](https://doi.org/10.1016/j.jconrel.2025.114371)
- **Source:** Semantic Scholar
- **llms.txt:** [View](https://science-database.com/technology/mrna-therapies/paper/s2-a78a3e2f0855aa15f95c762cf9f1848abb5938e6/llms.txt)

> Thiourea-modified poly(l-lysine) (PLL-T) carriers constructed by combinatorial side-chain modification with ionizable and hydrophobic isothiocyanates offer a potent and safe platform for mRNA therapeutics, demonstrating hydrogen bonding-driven carriers engineering as a versatile strategy to tune nucleic acid-carrier interactions.

### The Key Technique in the mRNA Vaccine Therapy

- **Authors:** Siyu Liu
- **Journal:** Academic Journal of Science and Technology
- **Published:** 2024
- **DOI:** [10.54097/9d1ahr43](https://doi.org/10.54097/9d1ahr43)
- **Source:** Semantic Scholar
- **Access:** Open Access
- **PDF:** [Download](https://drpress.org/ojs/index.php/ajst/article/download/25053/24517)
- **llms.txt:** [View](https://science-database.com/technology/mrna-therapies/paper/s2-9aabf50993a25aa9d09f6d24f6850f6eb0a047fc/llms.txt)

> The main key technologies based on mRNA drug design, such as in vitro transcription (IVT), nucleotide and cap and tail structure modification, were reviewed, followed by a brief introduction to mRNA purification methods and delivery systems.

---

*Generated by [science-database.com](https://science-database.com) — The Knowledge Interface*  
*Full data available via [JSON API](https://science-database.com/api/v1/technology/mrna-therapies)*